Record: found
Abstract: found
Article: not found

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Author(s): Jürgen Scheller, Roland S. G. Jones, Stefan Rose-John, Elizabeth Jones

Publication date: 2011-08-31

Journal: The Journal of clinical investigation

Keywords: immunology, Animals, Antibodies, Monoclonal, therapeutic use, Antibodies, Monoclonal, Humanized, Autoimmune Diseases, drug therapy, Cytokine Receptor gp130, Humans, Inflammation, Interleukin-6, Neoplasms, Receptors, Interleukin-6, genetics, Signal Transduction

Read this article at

ScienceOpenPublisher PMC

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.

Related collections

Author and article information

Journal

PubMed ID:: 21881215

PMC ID:: 3163962

DOI:: 10.1172/JCI57158

Data availability:

ScienceOpen disciplines: Chemistry

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Read this article at

Abstract

Related collections

Therapeutics and Clinical Risk Management

Author and article information

Journal

Comments

Comment on this article

Similar content 502

Cited by 147